<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2239">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729374</url>
  </required_header>
  <id_info>
    <org_study_id>NJGLVAC-001</org_study_id>
    <nct_id>NCT04729374</nct_id>
  </id_info>
  <brief_title>COVID-19 Vaccine Induced Adaptive Immune Responses</brief_title>
  <official_title>Longidutinal, Dynamic Analysis of COVID-19 Vaccine Induced Adaptive Immune Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory&#xD;
      syndrome coronavirus 2 (SARS-CoV-2)，resulting in more than 82 million confirmed cases and&#xD;
      caused around 1.8 million deaths, as of 2 January 2021. The ongoing pandemic still poses&#xD;
      unprecedented global threat to public health system worldwide. On December 31, 2020, the&#xD;
      joint prevention and control agency of China Council announced that Sinopharm SARS-CoV-2&#xD;
      inactivated vaccine had been conditionally approved by National Medical Products&#xD;
      Administration, and the protection rate was 79.34%. So far, more than 198 vaccines were&#xD;
      currently in preclinical or clinical development. The investigators aimed to initiate an&#xD;
      observational cohort of healthy individuals injected with SARS-CoV-2 Vaccine, which will&#xD;
      perform a longitudinal, comprehensive analysis of the SARS-CoV-2 vaccine Induced adaptive&#xD;
      immune responses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of anti-SARS-CoV-2 neutralizing antibody in serum</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of serum anti-SARS-CoV-2 binding antibody</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of anti-SARS-CoV-2 T cell response</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of SARS-CoV-2 infection</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of anti-SARS-CoV-2 B cell response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>SARS-CoV-2</condition>
  <condition>Vaccine</condition>
  <condition>COVID-19</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood (serum, plasma, and DNA)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy individuals to be injected with COVID-19 vaccine&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy and aged between 18 to 59 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High-risk epidemiology history within 14 days before enrollment&#xD;
&#xD;
          -  SARS-CoV-2 specific IgG or IgM positive in serum&#xD;
&#xD;
          -  Positive PCR test for SARS-CoV-2 from pharyngeal or anal swab samples&#xD;
&#xD;
          -  Axillary temperature of more than 37·0°C&#xD;
&#xD;
          -  Known allergy to any vaccine component&#xD;
&#xD;
          -  Thyroid disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuxin Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Drum Tower Hospital, Nanjing University Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Han Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Drum Tower Hospital, Nanjing University Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rui Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Drum Tower Hospital, Nanjing University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chao Wu, M.D., Ph.D</last_name>
    <phone>+8613809022921</phone>
    <email>dr.wu@nju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxin Chen, Ph.D</last_name>
    <phone>+8617714413628</phone>
    <email>yuxin_chen2015@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxin Chen</last_name>
    </contact>
    <investigator>
      <last_name>Chao Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Chao Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

